Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
CERO 
CERo Therapeutics Holdings, Inc. Common Stock (CERO)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
09/17/2025: CERO (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
2 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $45
1 Year Target Price $45
| 0 | Strong Buy |
| 1 | Buy |
| 1 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -34.99% | Avg. Invested days 60 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 09/17/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 6.83M USD | Price to earnings Ratio - | 1Y Target Price 45 |
Price to earnings Ratio - | 1Y Target Price 45 | ||
Volume (30-day avg) 2 | Beta 0.5 | 52 Weeks Range 4.27 - 896.00 | Updated Date 09/17/2025 |
52 Weeks Range 4.27 - 896.00 | Updated Date 09/17/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -379.05 |
Earnings Date
Report Date 2025-08-22 | When After Market | Estimate -6.21 | Actual -61.71 |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -156.89% | Return on Equity (TTM) - |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 12759003 | Price to Sales(TTM) - |
Enterprise Value 12759003 | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA - | Shares Outstanding 1205400 | Shares Floating 1102750 |
Shares Outstanding 1205400 | Shares Floating 1102750 | ||
Percent Insiders 3.55 | Percent Institutions 25.73 |
Upturn AI SWOT
CERo Therapeutics Holdings, Inc. Common Stock
Company Overview
History and Background
CERo Therapeutics Holdings, Inc. is a development stage company focused on developing and commercializing therapeutic solutions for unmet medical needs. Details regarding its founding year and significant milestones are scarce in publicly available information.
Core Business Areas
- Therapeutic Development: CERo Therapeutics Holdings, Inc. is focused on developing new therapeutic candidates in areas of significant unmet medical need.
Leadership and Structure
Detailed information about the company's leadership team and organizational structure is not readily available in the public domain.
Top Products and Market Share
Key Offerings
- CERo-001: This appears to be a lead drug candidate. Market share data and competitor information are not publicly available. It is likely still in clinical development. Competitor information depends on the specific indication it targets, but would include major pharmaceutical companies and other biotech firms working in the same area.
Market Dynamics
Industry Overview
The biotechnology industry is highly competitive and dynamic, characterized by significant investment in research and development, lengthy regulatory approval processes, and potential for high returns.
Positioning
As a development stage company, CERo Therapeutics Holdings, Inc. is positioned as an early-stage player aiming to develop innovative therapies. Its competitive advantage would depend on the uniqueness and efficacy of its drug candidates.
Total Addressable Market (TAM)
The potential TAM depends on the specific indications targeted by CERo's drug candidates. Given the lack of specific information about the target disease(s), it is difficult to estimate a TAM, but successful therapeutics addressing unmet needs can reach billions of dollars in annual sales. CERo Therapeutics Holdings, Inc.'s positioning within that TAM depends on clinical trial outcomes.
Upturn SWOT Analysis
Strengths
- Novel therapeutic approach (if applicable)
- Potential for high returns if successful
- Focus on unmet medical needs
Weaknesses
- Development stage company with no approved products
- High risk of failure in clinical trials
- Limited financial resources
- Lack of established market presence
Opportunities
- Successful clinical trials leading to regulatory approval
- Partnerships with larger pharmaceutical companies
- Expansion into new therapeutic areas
- Advancements in related technologies
Threats
- Clinical trial failures
- Competition from established pharmaceutical companies
- Regulatory hurdles
- Intellectual property disputes
- Inability to secure funding
Competitors and Market Share
Key Competitors
Competitive Landscape
The competitive landscape is not applicable without detailed information about CERo Therapeutics Holdings, Inc.'s specific therapeutic targets.
Growth Trajectory and Initiatives
Historical Growth: Historical growth is not applicable as a development stage company.
Future Projections: Future projections depend entirely on the success of its clinical trials and ability to secure funding. Analyst estimates are unlikely to be available.
Recent Initiatives: Recent initiatives are not publicly available and would likely involve clinical trial progress and fundraising efforts.
Summary
CERo Therapeutics Holdings, Inc. is a development stage biotechnology company with a focus on developing new therapeutic candidates. As such, it is a high-risk, high-reward investment opportunity. Its success depends heavily on the outcome of clinical trials and its ability to secure funding. Investors should be aware of the significant risks associated with investing in development stage biotech companies.
Peer Comparison
Sources and Disclaimers
Data Sources:
- SEC Filings
- Company Website
- Press Releases
Disclaimers:
The analysis is based on limited publicly available information and may not be comprehensive. Investing in biotechnology companies involves significant risks, and past performance is not indicative of future results. This analysis is not financial advice.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About CERo Therapeutics Holdings, Inc. Common Stock
Exchange NASDAQ | Headquaters South San Francisco, CA, United States | ||
IPO Launch date 2024-02-15 | CEO & Chair Mr. Christopher B. Ehrlich M.B.A. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 8 | Website https://www.cero.bio |
Full time employees 8 | Website https://www.cero.bio | ||
CERo Therapeutics Holdings, Inc., an immunotherapy company, focuses on advancing the development of engineered T cell therapeutics for the treatment of cancer. Its lead development candidate is CER-1236, an autologous T cell therapy candidate for the treatment of hematologic malignancies and solid tumors. The company was incorporated in 2021 and is based in South San Francisco, California.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.